Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Neutral on Quest Diagnostics, Lowers Price Target to $143

Credit Suisse analyst A.J. Rice maintains Quest Diagnostics (NYSE:DGX) with a Neutral and lowers the price target from $158 to $143.

byBenzinga Newsdesk

July 22, 2022

1 minute read

Credit Suisse analyst A.J. Rice maintains Quest Diagnostics (NYSE:DGX) with a Neutral and lowers the price target from $158 to $143.

Truist Securities Downgrades Nevro to Hold, Lowers Price Target to $105

By Benzinga Newsdesk

Today, 2:46 AM

Truist Securities analyst Kaila Krum downgrades Nevro (NYSE:NVRO) from Buy to Hold and lowers the price target from $165 to $105.

NVRO

Needham Initiates Coverage On Overstock.com with Buy Rating, Announces Price Target of $150 – Added to Conviction List

By Benzinga Newsdesk

Today, 2:46 AM

Needham analyst Anna Andreeva initiates coverage on Overstock.com (NASDAQ:OSTK) with a Buy rating and announces Price Target of $150, Added to Conviction List

OSTK

AZZ Raises FY22 EPS Guidance From $2.65-$3.05 To $2.90-$3.20 vs $3.03 Est.; Raises Sales Guidance From $855M-$935M To $865M-$925M vs $924.2M Est.

By Bill Haddad

Today, 2:46 AM

Mr. Ferguson added, "Due to the continued operating performance in our segments, we have revised our previously issued fiscal 2022 sales and earnings per share guidance. We now anticipate annual sales to be in the

AZZ